Senzime receives order from Switzerland
Press release: Uppsala, October 2, 2020. Senzime AB (publ) today announces that the company has received another order from its distributor Leuag in Switzerland. The order of TetraGraph systems with Philips Interface and disposable TetraSens sensors have been purchased to replace the hospitals current AMG systems. The order value amounts to approximately SEK 300 thousand and delivery will take place during the current month.
”We are continuously expanding our installed base of TetraGraph systems. Increased monitoring leads to increased safety, correct dosing, and fewer complications”, says Pia Renaudin, Senzime CEO
With almost 300 hospitals, Switzerland is an important market for Senzime.
“We currently have inquiries about TetraGraph from all university hospitals in Switzerland. We estimate that each installed TetraGraph consumes more than 1.5 TetraSens per day. We also see that the consumption of disposable sensors increases the more accustomed users become with TetraGraph”, says Claudia Stauffer, Sales Manager Leuag.
TetraGraph is a unique digital system that measures the presence and depth of neuromuscular blockade to enable the doctor to determine the correct drug dosage and assess when the patient is ready to breathe on their own without the risk of complications. In addition to Europe, Senzime has launched sales of TetraGraph in Japan, Australia, and the United States.
For further information, please contact:
Pia Renaudin, CEO of Senzime AB
Phone: +46 70-813 34 17, e-post: pia.renaudin@senzime.com
TO THE EDITORS
About Senzime
Senzime develops and markets systems, driven by unique algorithms and sensors, to follow patients ' nervous systems and electrical impulses – before, during and after surgery. The company's solution is called TetraGraph, a medical technology system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow health care guidelines and drug recommendations, TetraGraph contributes to shorter hospitalizations and lower health care costs – in a world where everyone wakes up safely after surgery. The vision is a world without narcotics-related complications. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, info@fnca.se, is Certified Adviser for Senzime. www.senzime.com
